Luspatercept Reduces Blood Transfusion Dependence in Lower-Risk MDS Anemia
December 2nd 2018Treatment with luspatercept significantly reduced the need for frequent red blood cell transfusions in nearly 53% of patients with anemia associated with low- to intermediate-risk myelodysplastic syndrome.
Read More
Entinostat/Pembrolizumab Combo Shows Promise in NSCLC Subgroup
September 26th 2018Ongoing analyses suggest enhanced clinical benefit is derived from the combined use of entinostat and pembrolizumab in a subgroup of patients with PD-1/PD-L1–refractory non–small cell lung cancer who have high levels of peripheral blood monocytes.
Read More
Adding Durvalumab to Chemoradiation Improves OS in Unresectable Stage III NSCLC
September 25th 2018Durvalumab induced a clinically meaningful improvement in overall survival compared with placebo in patients with stage III, unresectable non–small cell lung cancer who have not progressed following chemoradiotherapy.
Read More
Atezolizumab Regimen Improves PFS in Frontline Nonsquamous NSCLC
September 25th 2018The addition of atezolizumab to carboplatin/cisplatin in the first-line setting and to pemetrexed as maintenance therapy significantly improved progression free survival in patients with stage IV nonsquamous NSCLC.
Read More
FDA Grants Frontline Pembrolizumab Priority Review for Lower PD-L1 Cutoff in NSCLC
September 12th 2018The FDA has granted a priority review designation to single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with PD-L1 expression ≥1% and no EGFR or ALK genomic tumor aberrations.
Read More
Microsatellite Instability Status Links to Lynch Syndrome in Broad Array of Cancers
June 2nd 2018Microsatellite instability-high tumors are more likely to be associated with the presence of Lynch syndrome. Yet, 45% of patients with cancers not typically identified with Lynch syndrome actually qualify for germline genetic testing.
Read More
TLR9 Agonist May Reverse Resistance to PD-1 Inhibition in Melanoma
April 17th 2018Combination use of CMP-001, an intratumoral toll-like receptor 9 agonist, and pembrolizumab (Keytruda) showed clinical activity in reversing PD-1 checkpoint inhibition resistance in patients with metastatic melanoma.
Read More
Alternative Agent Shows Clinical Activity in Patients With Advanced Systemic Mastocytosis
December 10th 2017Treatment using BLU-285 (Avapritinib) induced clinically significant activity in patients with an advanced or aggressive form of systemic mastocytosis, according to data from an ongoing phase I trial.
Read More